# Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

> **NCT04349267** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 44 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** BMS-986315
- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT04349267
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04349267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04349267, "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04349267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*